Long Term Follow-Up After Preserflotm Microshunt Implantation
Published 2023 - 41st Congress of the ESCRS
Reference: PO0868 | Type: Free paper | DOI: 10.82333/v9vg-p926
Authors: Viktoria Constanze Brücher* 1 , Jens Storp 1 , Friederike Vietmeier 1 , Ralph-Laurent Merté 1 , Raphael Koch 2 , Nicole Eter 1
1Ophthalmology,University of Muenster,Muenster,Germany, 2Institue for Biometry and Clinical Research,University of Muenster,Muenster,Germany
Purpose
The Preserflo™ MicroShunt is a novel implant for the treatment of glaucoma. Long-term data are necessary to properly evaluate the effectiveness and safety of therapy, as is the case with all new technologies. This study's objective is to examine these factors in long-term patient statistics from PreserfloTM users at the Department of Ophthalmology, University Hospital Münster.
Setting
monocentric, retrospective
Methods
160 eyes from 160 patients who received Preserflo MicroShunt implantation at the Department of Ophthalmology at the University Hospital Münster were retrospectively enrolled in this study. Patient characteristics, treatment success rates, the number of adverse events and revision procedures, and the development of intraocular pressure (IOP) were examined. In addition, hazard ratios for the association of different parameters with lack of success were calculated. Changes in IOP were analyzed using the Wilcoxon sign rank test.
Results
The average IOP decreased from 23 ± 6.6 mmHg at baseline to 16 ± 7.7 mmHg after 12 months postoperatively (p < 0.01). After 12 months postoperatively, the average number of antiglaucomatous eyedrops decreased from 3 to 1 (p < 0.01). The overall success percentage was 61.9% (VE: 51.3%, QE: 10.6%). In 25% of cases, a revisions surgery was carried out.
Conclusions
The Preserflo™ MicroShunt significantly reduces IOP over a period of 12 months in glaucoma patients, regardless of disease severity. The frequency of postoperative adverse events and the number of revision operations were low.